Insulet Corporation is a medical devices business based in the US. Insulet Corporation shares (PODD) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $230.07 – a decrease of 0.76% over the previous week. Insulet Corporation employs 3,000 staff and has a trailing 12-month revenue of around $1.9 billion.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $230.07 |
|---|---|
| 52-week range | $128.68 - $243.98 |
| 50-day moving average | $214.80 |
| 200-day moving average | $193.10 |
| Wall St. target price | $243.69 |
| PE ratio | 41.5289 |
| Dividend yield | N/A |
| Earnings per share (TTM) | $5.54 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $232.51 from 2024-10-14
| 1 week (2024-10-10) | 0.57% |
|---|---|
| 1 month (2024-09-17) | -1.29% |
| 3 months (2024-07-17) | 17.64% |
| 6 months (2024-04-17) | 39.85% |
| 1 year (2023-10-17) | 64.46% |
|---|---|
| 2 years (2022-10-17) | 3.73% |
| 3 years (2021-10-15) | 300.49 |
| 5 years (2019-10-17) | 48.59% |
Valuing Insulet Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Insulet Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Insulet Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 42x. In other words, Insulet Corporation shares trade at around 42x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Insulet Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 3.5988. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Insulet Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Insulet Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $364 million.
The EBITDA is a measure of a Insulet Corporation's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $1.9 billion |
|---|---|
| Operating margin TTM | 11.18% |
| Gross profit TTM | $805.6 million |
| Return on assets TTM | 6.85% |
| Return on equity TTM | 50.93% |
| Profit margin | 21.11% |
| Book value | $14.24 |
| Market Capitalization | $16.1 billion |
TTM: trailing 12 months
We're not expecting Insulet Corporation to pay a dividend over the next 12 months.
Over the last 12 months, Insulet Corporation's shares have ranged in value from as little as $128.68 up to $243.98. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Insulet Corporation's is 1.212. This would suggest that Insulet Corporation's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts. .
Fundamental analysis of stocks can help you become a better investor and find the true value of stocks and other assets.
These are the stocks to buy when you don’t have much to spend.
Explore the best bonuses for opening a new brokerage account.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out the best-performing ETFs so far in 2024.
Read our beginner’s guide to trading options in the US.